FilingReader Intelligence
Jagsonpal Pharmaceuticals doubles profits in Q1FY26
July 26, 2025 at 11:50 AM UTC•By FilingReader AI
Jagsonpal Pharmaceuticals' Q1FY26 revenue surged 23.1% to ₹756m, with operating EBITDA increasing 24.1% to ₹157m. Net profit more than doubled to ₹108m, boosting cash position to ₹1,609m.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:JAGSNPHARM•Bombay Stock Exchange
News Alerts
Get instant email alerts when Jagsonpal Pharmaceuticals publishes news
Free account required • Unsubscribe anytime